8-K: Arvinas Reports Q4/FY25 Results, Advances PROTAC Pipeline

Arvinas announced its Q4 and full-year 2025 financial results, highlighting significant pipeline progress and a cash runway into the second half of 2028.

Summary

• Arvinas reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a comprehensive corporate update.
• The company's cash, cash equivalents, and marketable securities totaled $685.4 million as of December 31, 2025, a decrease from $1,039.4 million in 2024, but projected to fund operations into the second half of 2028.
• Full-year 2025 GAAP Research and Development (R&D) expenses decreased to $285.2 million from $348.2 million in 2024, while GAAP General and Administrative (G&A) expenses decreased to $95.9 million from $165.4 million.
• Full-year 2025 revenue was $262.6 million, a slight decrease from $263.4 million in 2024, primarily influenced by changes in collaboration agreements.
• The net loss for the full year 2025 significantly improved to $(80.8) million, compared to a net loss of $(198.9) million in 2024.
• Randy Teel, Ph.D., was appointed President, Chief Executive Officer, and Director, succeeding John Houston, Ph.D., who retired from his executive role but remains a Board member and consultant.
• Key pipeline advancements include ARV-102 (Parkinson's disease) with Phase 1 data accepted for presentation in March 2026, ARV-806 (KRAS G12D) completing dose escalation ahead of schedule, and ARV-393 (BCL6) showing multiple responses in early cohorts.
• A first-in-human Phase 1 trial for ARV-027 (polyQ-AR degrader) was initiated, and ARV-6723 (HPK1 degrader), the first immuno-oncology PROTAC, is on track for a Phase 1 trial in mid-2026.
• Vepdegestrant, developed in collaboration with Pfizer, has a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026, for its New Drug Application (NDA).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by significant pipeline advancements, particularly the positive preclinical and early clinical data for multiple PROTAC degraders, and the clear path to potential FDA approval for vepdegestrant. The improved financial efficiency and extended cash runway further bolster confidence.

Positives

• Cash, cash equivalents, and marketable securities of $685.4 million as of December 31, 2025, are sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028.
• The full-year 2025 net loss significantly improved to $(80.8) million, compared to $(198.9) million in 2024, demonstrating enhanced financial performance.
• GAAP R&D expenses decreased by $63.0 million year-over-year, and GAAP G&A expenses decreased by $69.5 million year-over-year, reflecting improved cost management and operational efficiency.
• ARV-102 Phase 1 clinical data in patients with Parkinson's disease, including disease-relevant pathway biomarker results, has been accepted for oral presentation at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) in March 2026.
• ARV-806 (KRAS G12D degrader) completed dose escalation for once-weekly administration ahead of plan due to faster-than-anticipated enrollment in its Phase 1 clinical trial.
• Preclinical data for ARV-806 demonstrated >25-fold greater potency in reducing cancer cell proliferation and >40-fold higher potency in degrading KRAS G12D protein compared to comparable clinical-stage G12D degraders.
• ARV-393 (BCL6 degrader) showed multiple responses in early cohorts of its Phase 1 trial in patients with non-Hodgkin's lymphoma, even at doses below the predicted effective exposure level.
• Preclinical data supports mechanistic synergies and enhanced antitumor activity when combining ARV-393 and glofitamab, achieving 81-91% tumor growth inhibition compared to 36-38% for single agents.
• A first-in-human Phase 1 clinical trial was initiated for ARV-027 (oral PROTAC polyQ-AR degrader) in healthy volunteers.
• Preclinical data for ARV-027 demonstrated robust degradation of polyQ-AR in human myotubes and improved muscle grip strength and restored muscle endurance in an SBMA mouse model.
• ARV-6723 (oral PROTAC HPK1 degrader) demonstrated anti-tumor efficacy superior to anti-PD1 or a clinical HPK1 inhibitor as a single agent in preclinical models.
• Vepdegestrant, in the VERITAC-2 Phase 3 study, demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant in patients with ER+/HER2advanced breast cancer.
• Vepdegestrant's New Drug Application (NDA) is under FDA review with a PDUFA action date of June 5, 2026, and has been granted Fast Track designation by the FDA.

Negatives

• Cash, cash equivalents, and marketable securities decreased by $354.0 million for the 12 months ended December 31, 2025, primarily due to $261.0 million in cash used in operations and $91.9 million in common share repurchases.
• Fourth quarter 2025 revenue decreased significantly to $9.5 million from $59.2 million in Q4 2024, mainly due to the completion of technology transfer for Novartis agreements and a decrease from the Vepdegestrant collaboration.
• The net loss for the fourth quarter 2025 worsened to $(67.4) million, compared to $(45.1) million in Q4 2024.

Risks

• Whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, ARV-806, ARV-393, ARV-027, and whether clinical trials will be initiated and completed, and results received on expected timelines or at all.
• Whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant.
• Risks related to Arvinas' expectations regarding the potential clinical benefit of its product candidates.
• Risks and uncertainties related to the identification of a third party for the commercialization and potential future development of vepdegestrant.
• Risks and uncertainties relating to regulatory applications and related approval timelines, including with respect to the New Drug Application for vepdegestrant.
• The risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority, or whether regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of product candidates, including vepdegestrant.
• Arvinas' ability to protect its intellectual property portfolio.
• Arvinas' reliance on third parties for various aspects of its business.
• Potential for early termination of any of Arvinas' collaborations.
• The impact of previously announced workforce reductions on Arvinas' business and reputation.
• Whether Arvinas will be able to raise capital when needed.
• Whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements.

Future Outlook

Arvinas anticipates delivering multiple value-driving milestones in 2026, including data readouts from ARV-102, ARV-806, and ARV-393. The company plans to initiate a Phase 1b clinical trial for ARV-102 in progressive supranuclear palsy (PSP) in the first half of 2026, with a potential registrational trial in late 2026. Initial clinical data for ARV-806 is expected in 2026, and updated clinical data for ARV-393 is anticipated in the second half of 2026, alongside the initiation of a combination cohort with glofitamab in the first half of 2026. The first immuno-oncology PROTAC, ARV-6723, is slated to begin a Phase 1 trial in mid-2026. For vepdegestrant, a PDUFA action date of June 5, 2026, is set, and Arvinas and Pfizer plan to identify a commercialization partner. The company projects its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2028.

Management Comments

• "2025 was marked by meaningful progress across our pipeline and was a truly transformative year for the Company."
• "In addition to submitting our first new drug application, which sets the stage for the potential first ever FDA approval of a PROTAC degrader, we redefined our strategic path and sharpened our focus within our pipeline to maximize the compelling opportunities ahead in each of our core areas of focus."
• "With four ongoing clinical trials across our oncology and neurology portfolios, including the recently initiated first-in-human trial of our polyQ-AR degrader, ARV-027, we believe we have the potential to bring truly differentiated treatments to millions of patients in areas of significant unmet medical need."

Industry Context

StockSavvy.ai notes that Arvinas continues to solidify its position as a leader in the targeted protein degradation (PROTAC) space, a rapidly evolving area of drug discovery. The advancement of multiple clinical candidates across oncology and neurology, particularly the potential first FDA approval of a PROTAC degrader with vepdegestrant, underscores the maturation of this technology. The focus on difficult-to-drug targets like KRAS G12D and BCL6, and the expansion into immuno-oncology with ARV-6723, aligns with broader industry trends seeking novel mechanisms for intractable diseases. The strategic refinement and pipeline focus, coupled with a strong cash runway, position Arvinas to capitalize on its innovative platform in a competitive biotech landscape.

Comparison to Industry Standards

• ARV-806 demonstrated >25-fold greater potency in reducing cancer cell proliferation compared with clinical-stage KRAS inhibitors and degraders.
• ARV-806 showed >40-fold higher potency in degrading KRAS G12D protein compared with a comparable clinical-stage G12D degrader.
• ARV-6723, as a single agent, demonstrated anti-tumor efficacy superior to anti-PD1 or a clinical HPK1 inhibitor in preclinical models.
• Vepdegestrant, in the VERITAC-2 Phase 3 study, demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant, a standard endocrine-based therapy for ER+/HER2advanced breast cancer.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to extended cash runway, improved financial performance (reduced net loss, lower expenses), and significant pipeline progress with multiple upcoming data readouts and a potential FDA approval for vepdegestrant.
• Patients: Potential for new, differentiated treatments in areas of high unmet medical need across oncology and neurology, including Parkinson's disease, KRAS G12D-mutated cancers, non-Hodgkin's lymphoma, SBMA, and ER+/HER2advanced breast cancer.
• Partners (Pfizer, Novartis): Continued collaboration with Pfizer on vepdegestrant towards a PDUFA date, and successful completion of technology transfer with Novartis, indicating ongoing and successful partnerships.

Next Steps

• Present ARV-102 Phase 1 clinical data in Parkinson's disease at the AD/PD Conference in March 2026.
• Initiate Phase 1b clinical trial for ARV-102 in patients with progressive supranuclear palsy (PSP) in 1H 2026, pending regulatory feedback.
• Potentially initiate a registrational trial for ARV-102 in PSP in late 2026, pending regulatory feedback.
• Continue enrollment in the Phase 1 trial of ARV-806 in patients with solid tumors harboring KRAS G12D mutations.
• Share initial clinical data for ARV-806 in patients with solid tumors harboring KRAS G12D mutations in 2026.
• Anticipate sharing updated clinical data from the ongoing Phase 1 clinical trial for ARV-393 in patients with relapsed/refractory non-Hodgkin's lymphoma at a medical congress in 2H 2026.
• Initiate enrollment of a combination cohort with glofitamab for ARV-393 in patients with diffuse large B-cell lymphoma (DLBCL) in 1H 2026.
• Continue enrollment in the Phase 1 clinical trial for ARV-027 in healthy volunteers.
• Initiate Phase 1 clinical trial for ARV-6723 in patients with advanced solid tumors in mid-2026, pending regulatory feedback.
• Present preclinical data evaluating antitumor and unique immunomodulatory activity of ARV-6723 in IO-resistant models compared to standard of care checkpoint inhibition in 1H 2026.
• Present preclinical data evaluating the activity and selectivity of novel pan-KRAS degrader in multiple KRAS mutants and differentiation over RAS (ON) or pan-KRAS inhibitors at AACR-RAS in March 2026.
• Present preclinical data evaluating the efficacy of a novel pan-KRAS degrader in a KRAS syngeneic model, as well as associated immune microenvironment changes in 1H 2026.
• Identify and select a partner with the capabilities and expertise to maximize the commercial potential of vepdegestrant.
• Advance towards Prescription Drug User Fee Act (PDUFA) action date for vepdegestrant on June 5, 2026.

Key Dates

Recommendation

The filing presents a compelling narrative of significant clinical and financial progress. The extended cash runway into H2 2028, coupled with a substantial reduction in net loss and operating expenses, demonstrates strong financial management. Critically, the pipeline is advancing robustly, with multiple programs showing promising preclinical and early clinical data, including ARV-806's superior potency and ARV-393's early responses. The upcoming PDUFA date for vepdegestrant represents a near-term, high-impact catalyst for potential first-in-class PROTAC approval. The leadership transition appears smooth, with the former CEO remaining on the board. These factors collectively suggest strong upside potential for investors.

Keywords

PROTAC, Protein Degradation, Biotechnology, Oncology, Neurology, Parkinson's Disease, KRAS G12D, Non-Hodgkin Lymphoma, Spinal Bulbar Muscular Atrophy, Breast Cancer, Vepdegestrant, ARV-102, ARV-806, ARV-393, ARV-027, ARV-6723, Clinical Trials, FDA Approval, Financial Results, Biopharma